Cornelia Schneider
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cornelia Schneider has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Susan S. Jick
Boston Collaborative Drug Surveillance Program, Boston University, Boston, Massachusetts, USA
15 shared publications - Christoph Rudolf Meier
Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
12 shared publications - Christian Meier
Division of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Basel, Switzerland
6 shared publications Elisabeth Zemp
Swiss Tropical and Public Health Institute, Switzerland; University of Basel, Switzerland
5 shared publications- Samuel S. Allemann
Pharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland
5 shared publications - Carola A. Huber
Department of Health Sciences, Helsana Group, Zurich, Switzerland
4 shared publications
Latest Publications
- Open Access
- 8 May 2026
- Published by Springer Nature in Journal of Public Health
From 2002 to 2022: sex-specific trends in diabetes prevalence and risk factors in Switzerland
Aim: This study assesses sex-specific trends in diabetes prevalence and associated risk factors in the Swiss population between 2002 and 2022. Subject and methods: We conducted a repeated cross-sectional analysis using data from the Swiss Health Surveys in 2002 ( n = 18,654) and 2022 ( n = 21,903), which is representative of the Swiss population. Participants’ diabetes status, body mass index (BMI), physical activity, education, lifestyle behaviors, and cardiometabolic risk factors were assessed and quantified using sex-stratified logistic regressions, and Oaxaca-Blinder decomposition. Results: Diabetes prevalence increased from 4.4% in 2002 to 6.4% in 2022 (men 4.8% to 7.4%; women 4.1% to 5.5%). Obesity (BMI ≥ 30 kg/m 2 ) became more common among individuals with diabetes (men 20.8% to 31.6%; women 22.7% to 26.0%) and was the factor most strongly associated with diabetes with BMI 18.5–24.9 kg/m 2 as a reference, with an odds ratio (OR) of 2.74 (95% CI [2.43–3.09]) in men and 2.91 (95% CI [2.60–3.27]) in women. Combined BMI ≥ 30 kg/m 2 and physically active conferred higher risk with an OR of 5.05 (95% CI [4.66–5.46]) than BMI 18.5–24.9 kg/m 2 and physically inactive with 2.09 (95% CI [1.89–2.30]). The Oaxaca-Blinder decomposition showed that sex differences in diabetes risk were predominantly explained by age and lifestyle factors differences in 2002, and by differential effects of these factors in 2022. Conclusion: Diabetes prevalence rose in Switzerland between 2002 and 2022, with BMI remaining the dominant modifiable risk factor, followed by physical activity. Prevention strategies should prioritize weight management, while promoting healthy lifestyle behaviors across all groups.
- 8 May 2026
- Published by Springer Nature in Journal of Public Health
Open AccessFrom 2002 to 2022: sex-specific trends in diabetes prevalence and risk factors in Switzerland
Aim: This study assesses sex-specific trends in diabetes prevalence and associated risk factors in the Swiss population between 2002 and 2022. Subject and methods: We conducted a repeated cross-sectional analysis using data from the Swiss Health Surveys in 2002 ( n = 18,654) and 2022 ( n = 21,903), which is representative of the Swiss population. Participants’ diabetes status, body mass index (BMI), physical activity, education, lifestyle behaviors, and cardiometabolic risk factors were assessed and quantified using sex-stratified logistic regressions, and Oaxaca-Blinder decomposition. Results: Diabetes prevalence increased from 4.4% in 2002 to 6.4% in 2022 (men 4.8% to 7.4%; women 4.1% to 5.5%). Obesity (BMI ≥ 30 kg/m 2 ) became more common among individuals with diabetes (men 20.8% to 31.6%; women 22.7% to 26.0%) and was the factor most strongly associated with diabetes with BMI 18.5–24.9 kg/m 2 as a reference, with an odds ratio (OR) of 2.74 (95% CI [2.43–3.09]) in men and 2.91 (95% CI [2.60–3.27]) in women. Combined BMI ≥ 30 kg/m 2 and physically active conferred higher risk with an OR of 5.05 (95% CI [4.66–5.46]) than BMI 18.5–24.9 kg/m 2 and physically inactive with 2.09 (95% CI [1.89–2.30]). The Oaxaca-Blinder decomposition showed that sex differences in diabetes risk were predominantly explained by age and lifestyle factors differences in 2002, and by differential effects of these factors in 2022. Conclusion: Diabetes prevalence rose in Switzerland between 2002 and 2022, with BMI remaining the dominant modifiable risk factor, followed by physical activity. Prevention strategies should prioritize weight management, while promoting healthy lifestyle behaviors across all groups.
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Pharmacogenomics and Personalized Medicine
- Vol. ume 19, 1-12
Population-Based Assessment of Phenoconversion Potential in Switzerland: A Claims Data Study of Key Drug-Metabolizing Enzymes and Transporters
Drug-drug-gene interactions can alter drug exposure and thereby increase the risk of clinically relevant outcomes, such as concentration-dependent toxicity (eg, tacrolimus toxicity in the context of altered CYP3A4/5 activity) or reduced treatment effectiveness. Despite their emerging relevance in clinical research, drug-drug-gene interactions remain understudied and are often ignored in clinical practice. Our objective was to assess the risk of phenoconversion by identifying potential drug-drug-gene interactions involving the transporters OATP1B1 and BCRP and the enzymes CYP2B6 and CYP3A4/5 in the Swiss population. Using claims data from the Helsana basic health insurance, we identified all persons of all ages with at least one drug claim between 2017 and 2021 and with Helsana basic health insurance coverage for at least one full year. For the five-year analysis, only persons with insurance for the entire five-year period were included. Within this study population, we assessed and ranked the frequency of potential drug-drug-gene interactions of a pharmacogenetic substrate and an inhibitor/inducer of OATP1B1, BCRP, CYP2B6, or CYP3A4/5. Potential drug-drug-gene interactions were defined as the co-occurrence of a pharmacogenetic substrate and an inhibitor/inducer within a 30- or 5-days window. During the entire five-year period, 18’523 (2.1%) and 12’645 (1.4%) individuals were exposed to potential drug-drug-gene interactions using the 30-day and 5-day windows, respectively. Potential drug-drug-gene interactions most frequently involved CYP3A4/5 (81.0% and 85.3%), followed by CYP2B6 (10.9% and 8.7%) and OATP1B1 (8.7% and 13.3%). The top three drug classes involved were nervous system drugs (75.1%), cardiovascular drugs (10.6%), and dermatologicals (4.0%). Quetiapine ranked first in the number of involved drug pairs, with quetiapine – metamizole being the predominant drug pair. In Switzerland, two out of 100 persons taking drugs metabolized or transported by OATP1B1, BCRP, CYP2B6, and CYP3A4/5 are at potential risk of phenoconversion, predominantly involving CYP3A4/5. These findings quantify real-world phenoconversion potential at the population level and underscore the need for outcome- and genotype-linked studies to determine clinical relevance. As this study was not designed to assess clinical outcomes, future genotype- and outcome-linked investigations are required to determine the actual impact on adverse drug reactions or treatment effectiveness.
- 1 May 2026
- Published by Taylor & Francis in Pharmacogenomics and Personalized Medicine
- Vol. ume 19, 1-12
Open AccessPopulation-Based Assessment of Phenoconversion Potential in Switzerland: A Claims Data Study of Key Drug-Metabolizing Enzymes and Transporters
Drug-drug-gene interactions can alter drug exposure and thereby increase the risk of clinically relevant outcomes, such as concentration-dependent toxicity (eg, tacrolimus toxicity in the context of altered CYP3A4/5 activity) or reduced treatment effectiveness. Despite their emerging relevance in clinical research, drug-drug-gene interactions remain understudied and are often ignored in clinical practice. Our objective was to assess the risk of phenoconversion by identifying potential drug-drug-gene interactions involving the transporters OATP1B1 and BCRP and the enzymes CYP2B6 and CYP3A4/5 in the Swiss population. Using claims data from the Helsana basic health insurance, we identified all persons of all ages with at least one drug claim between 2017 and 2021 and with Helsana basic health insurance coverage for at least one full year. For the five-year analysis, only persons with insurance for the entire five-year period were included. Within this study population, we assessed and ranked the frequency of potential drug-drug-gene interactions of a pharmacogenetic substrate and an inhibitor/inducer of OATP1B1, BCRP, CYP2B6, or CYP3A4/5. Potential drug-drug-gene interactions were defined as the co-occurrence of a pharmacogenetic substrate and an inhibitor/inducer within a 30- or 5-days window. During the entire five-year period, 18’523 (2.1%) and 12’645 (1.4%) individuals were exposed to potential drug-drug-gene interactions using the 30-day and 5-day windows, respectively. Potential drug-drug-gene interactions most frequently involved CYP3A4/5 (81.0% and 85.3%), followed by CYP2B6 (10.9% and 8.7%) and OATP1B1 (8.7% and 13.3%). The top three drug classes involved were nervous system drugs (75.1%), cardiovascular drugs (10.6%), and dermatologicals (4.0%). Quetiapine ranked first in the number of involved drug pairs, with quetiapine – metamizole being the predominant drug pair. In Switzerland, two out of 100 persons taking drugs metabolized or transported by OATP1B1, BCRP, CYP2B6, and CYP3A4/5 are at potential risk of phenoconversion, predominantly involving CYP3A4/5. These findings quantify real-world phenoconversion potential at the population level and underscore the need for outcome- and genotype-linked studies to determine clinical relevance. As this study was not designed to assess clinical outcomes, future genotype- and outcome-linked investigations are required to determine the actual impact on adverse drug reactions or treatment effectiveness.
- Open Access
- 15 December 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e76811
IL-6/GP130/JAK/STAT3 Pathway Activation in Pancreatic Ductal Adenocarcinoma and Its Association With Clinical Features: Protocol for a Retrospective Cross-Sectional Study
Background: The proinflammatory cytokine interleukin 6 (IL-6) contributes to pancreatic tumorigenesis by activating the Janus kinase (JAK)–signal transducer and activator of transcription 3 (STAT3) signaling cascade. Targeting the IL-6/glycoprotein 130 (GP130)/JAK/STAT3 axis may therefore represent a promising therapeutic approach for pancreatic adenocarcinoma. Objective: This study investigates the activation of the IL-6/GP130/JAK/STAT3 pathway in archived biopsy samples from patients with pancreatic adenocarcinoma, quantifying its expression in both tumor and stromal compartments. In addition, potential associations between pathway activation and clinical outcomes are explored, including tumor stage, patient survival, and metabolic parameters such as diabetes, use of oral antidiabetic drugs, insulin therapy, and hemoglobin A 1c levels. Methods: We will conduct a retrospective cross-sectional analysis of patients with pancreatic adenocarcinoma treated at the Cantonal Hospital of Fribourg, Switzerland, between 2010 and 2025. Eligible cases are identified through tumor board records. Archived pathology specimens will be immunostained using a phospho-STAT3 antibody to assess GP130 receptor activation. The percentage of positively stained cells will be quantified separately for tumor tissue, stroma, and adjacent normal tissue using QPath software. Sample size calculations are based on the assumption that patients with higher IL-6 pathway activation have poorer prognoses. Detecting a 5% difference in activation requires 84 patients per group for 90% power or 104 per group for 95% power. Diabetes will be analyzed as a dichotomous variable, while IL-6/GP130/JAK/STAT3 activation will be treated as a continuous variable. Descriptive statistics will summarize pathway activation and clinical variables. Mean differences between groups will be compared, and survival outcomes will be evaluated using Cox proportional hazards models. Hazard ratios will be calculated for all metabolic parameters to assess potential associations between pathway activation and diabetes. All analyses will include 95% CIs, with missing data reported transparently. Results: This project is supported by a research grant from the Cantonal Hospital of Fribourg (HFR 2/2021 and 4/2022). It was approved by the Ethics Committee of Bern, Switzerland (project 2024‐01215). As of October 12, 2025, clinical records from 150 patients have been identified. Screening of additional patient records from 2024 to 2025 is ongoing. Conclusions: This study represents one of the first translational investigations of IL-6/GP130/JAK/STAT3 signaling in pancreatic adenocarcinoma. By correlating molecular pathway activation with clinical and metabolic features, it will provide new insights into disease heterogeneity and support the development of personalized, pathway-targeted therapeutic strategies.
- 15 December 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e76811
Open AccessIL-6/GP130/JAK/STAT3 Pathway Activation in Pancreatic Ductal Adenocarcinoma and Its Association With Clinical Features: Protocol for a Retrospective Cross-Sectional Study
Background: The proinflammatory cytokine interleukin 6 (IL-6) contributes to pancreatic tumorigenesis by activating the Janus kinase (JAK)–signal transducer and activator of transcription 3 (STAT3) signaling cascade. Targeting the IL-6/glycoprotein 130 (GP130)/JAK/STAT3 axis may therefore represent a promising therapeutic approach for pancreatic adenocarcinoma. Objective: This study investigates the activation of the IL-6/GP130/JAK/STAT3 pathway in archived biopsy samples from patients with pancreatic adenocarcinoma, quantifying its expression in both tumor and stromal compartments. In addition, potential associations between pathway activation and clinical outcomes are explored, including tumor stage, patient survival, and metabolic parameters such as diabetes, use of oral antidiabetic drugs, insulin therapy, and hemoglobin A 1c levels. Methods: We will conduct a retrospective cross-sectional analysis of patients with pancreatic adenocarcinoma treated at the Cantonal Hospital of Fribourg, Switzerland, between 2010 and 2025. Eligible cases are identified through tumor board records. Archived pathology specimens will be immunostained using a phospho-STAT3 antibody to assess GP130 receptor activation. The percentage of positively stained cells will be quantified separately for tumor tissue, stroma, and adjacent normal tissue using QPath software. Sample size calculations are based on the assumption that patients with higher IL-6 pathway activation have poorer prognoses. Detecting a 5% difference in activation requires 84 patients per group for 90% power or 104 per group for 95% power. Diabetes will be analyzed as a dichotomous variable, while IL-6/GP130/JAK/STAT3 activation will be treated as a continuous variable. Descriptive statistics will summarize pathway activation and clinical variables. Mean differences between groups will be compared, and survival outcomes will be evaluated using Cox proportional hazards models. Hazard ratios will be calculated for all metabolic parameters to assess potential associations between pathway activation and diabetes. All analyses will include 95% CIs, with missing data reported transparently. Results: This project is supported by a research grant from the Cantonal Hospital of Fribourg (HFR 2/2021 and 4/2022). It was approved by the Ethics Committee of Bern, Switzerland (project 2024‐01215). As of October 12, 2025, clinical records from 150 patients have been identified. Screening of additional patient records from 2024 to 2025 is ongoing. Conclusions: This study represents one of the first translational investigations of IL-6/GP130/JAK/STAT3 signaling in pancreatic adenocarcinoma. By correlating molecular pathway activation with clinical and metabolic features, it will provide new insights into disease heterogeneity and support the development of personalized, pathway-targeted therapeutic strategies.
- Open Access
- 17 September 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (8) , 1434-1441
Performance of the EndPAC risk score for pancreatic cancer in new onset diabetes patients with missing data – a database study in the British population
- 17 September 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (8) , 1434-1441
Open AccessPerformance of the EndPAC risk score for pancreatic cancer in new onset diabetes patients with missing data – a database study in the British population
- Open Access
- 1 August 2025
- Published by Taylor & Francis in Pharmacogenomics and Personalized Medicine
- Vol. ume 18, 197-208
The Prevalence of Potential Drug-Drug-Gene Interactions: A Descriptive Study Using Swiss Claims Data
Purpose: We aimed to determine the prevalence of interactions between PGx drugs metabolized by CYP2C9, CYP2C19, and CYP2D6 and drugs that act as inhibitors or inducers of those enzymes in the Swiss population. Patients and Methods: We defined concomitant use of PGx drugs and inhibitors/inducers as instances where a claim of a PGx drug and a claim of an inducer or inhibitor concerning the same enzyme were made within a specified temporal window, either ± 5 days or ± 30 days. We assessed concomitant drug use between 2017 and 2021, using claims data from a Swiss insurance company (Helsana). Results: Out of 894,748 individuals continuously insured, between 17.4% (± 5-days window) and 24.8% (± 30-days window) were exposed to potentially interacting drug pairs, with 1.5% to 2.2% being exposed to potentially strong interacting drug pairs. Individuals exposed to potentially interacting drugs were more frequently female, older and took a greater number of drugs than the general population. The majority of potential interactions were associated with CYP2D6 or CYP2C19. Conclusion: In light of the high prevalence of the simultaneous use of PGx drugs with inhibitor and inducer drugs, it is imperative to consider non-genetic factors, such as drug-induced phenoconversions, when interpreting PGx test results.
- 1 August 2025
- Published by Taylor & Francis in Pharmacogenomics and Personalized Medicine
- Vol. ume 18, 197-208
Open AccessThe Prevalence of Potential Drug-Drug-Gene Interactions: A Descriptive Study Using Swiss Claims Data
Purpose: We aimed to determine the prevalence of interactions between PGx drugs metabolized by CYP2C9, CYP2C19, and CYP2D6 and drugs that act as inhibitors or inducers of those enzymes in the Swiss population. Patients and Methods: We defined concomitant use of PGx drugs and inhibitors/inducers as instances where a claim of a PGx drug and a claim of an inducer or inhibitor concerning the same enzyme were made within a specified temporal window, either ± 5 days or ± 30 days. We assessed concomitant drug use between 2017 and 2021, using claims data from a Swiss insurance company (Helsana). Results: Out of 894,748 individuals continuously insured, between 17.4% (± 5-days window) and 24.8% (± 30-days window) were exposed to potentially interacting drug pairs, with 1.5% to 2.2% being exposed to potentially strong interacting drug pairs. Individuals exposed to potentially interacting drugs were more frequently female, older and took a greater number of drugs than the general population. The majority of potential interactions were associated with CYP2D6 or CYP2C19. Conclusion: In light of the high prevalence of the simultaneous use of PGx drugs with inhibitor and inducer drugs, it is imperative to consider non-genetic factors, such as drug-induced phenoconversions, when interpreting PGx test results.
- Open Access
- 1 April 2025
- Published by Taylor & Francis in Pragmatic and Observational Research
- Vol. ume 16, 129-134
Comprehensive Description of an Automated Drug Dispensing System Database
Medifilm is a company that blisters drug therapies recorded by pharmacists in the Medifilm software. The Medifilm dataset collates this information and provides details on drug substances, dosages, pharmacotherapy duration, the sequence of therapies, as well as demographic data on the patients. This article aims to provide an overview of the database, to describe the contents, and to demonstrate possibilities for researchers. The database and the recorded information were described. Furthermore, the data coverage was characterized in terms of the number of available pharmacies, patients, and their drug regimens. The database has been recording data since 2013 and has registered 470,801 blistered therapies for 45,594 patients ordered by 441 pharmacies so far. The longitudinal nature of the database allows researchers to study drug utilization, including medication changes, initiations, and discontinuations over time.
- 1 April 2025
- Published by Taylor & Francis in Pragmatic and Observational Research
- Vol. ume 16, 129-134
Open AccessComprehensive Description of an Automated Drug Dispensing System Database
Medifilm is a company that blisters drug therapies recorded by pharmacists in the Medifilm software. The Medifilm dataset collates this information and provides details on drug substances, dosages, pharmacotherapy duration, the sequence of therapies, as well as demographic data on the patients. This article aims to provide an overview of the database, to describe the contents, and to demonstrate possibilities for researchers. The database and the recorded information were described. Furthermore, the data coverage was characterized in terms of the number of available pharmacies, patients, and their drug regimens. The database has been recording data since 2013 and has registered 470,801 blistered therapies for 45,594 patients ordered by 441 pharmacies so far. The longitudinal nature of the database allows researchers to study drug utilization, including medication changes, initiations, and discontinuations over time.
- Open Access
- 20 February 2025
- Published by Springer Nature in Drug Safety
- Vol. 48 (6) , 689-696
Pharmacogenetic Testing in the Outpatient Setting in Switzerland: A Descriptive Study Using Swiss Claims Data
Background In Switzerland, consumers are exposed to drugs with pharmacogenetic (PGx) recommendations in 78% of cases. Pre-emptive PGx testing for seven drugs (abacavir, carbamazepine, 6-mercaptopurine, azathioprine, 5-fluorouracil, capecitabine, and irinotecan) has been covered by basic health insurance since 2017. PGx testing for other drugs is only covered if it is reactive and prescribed by a clinical pharmacologist. No data are yet available on the implementation of PGx testing in the outpatient setting. Aim The objective of this study was to determine the prevalence of ambulatory PGx testing in the Swiss population, to characterize PGx-tested individuals, and to identify the most commonly used drugs before and after PGx testing. Methods We assessed the prevalence of PGx testing in Switzerland and characterized individuals who underwent PGx testing between 2017 and 2021 using claims data from a large health insurance company. Results Of 894,748 individuals registered for the entire study period, only 817 (0.09%) underwent PGx testing. Those who underwent PGx testing were more frequently female and claimed more drugs and PGx drugs than those who did not undergo PGx testing. The drugs used before and after PGx testing differed, and fewer drugs with reimbursement for pre-emptive PGx testing were included before PGx testing. Conclusion In Switzerland, personalized pharmacotherapy has the potential to be improved, as only 0.09% of the studied population underwent PGx testing, despite 77.4% claiming PGx drugs.
- 20 February 2025
- Published by Springer Nature in Drug Safety
- Vol. 48 (6) , 689-696
Open AccessPharmacogenetic Testing in the Outpatient Setting in Switzerland: A Descriptive Study Using Swiss Claims Data
Background In Switzerland, consumers are exposed to drugs with pharmacogenetic (PGx) recommendations in 78% of cases. Pre-emptive PGx testing for seven drugs (abacavir, carbamazepine, 6-mercaptopurine, azathioprine, 5-fluorouracil, capecitabine, and irinotecan) has been covered by basic health insurance since 2017. PGx testing for other drugs is only covered if it is reactive and prescribed by a clinical pharmacologist. No data are yet available on the implementation of PGx testing in the outpatient setting. Aim The objective of this study was to determine the prevalence of ambulatory PGx testing in the Swiss population, to characterize PGx-tested individuals, and to identify the most commonly used drugs before and after PGx testing. Methods We assessed the prevalence of PGx testing in Switzerland and characterized individuals who underwent PGx testing between 2017 and 2021 using claims data from a large health insurance company. Results Of 894,748 individuals registered for the entire study period, only 817 (0.09%) underwent PGx testing. Those who underwent PGx testing were more frequently female and claimed more drugs and PGx drugs than those who did not undergo PGx testing. The drugs used before and after PGx testing differed, and fewer drugs with reimbursement for pre-emptive PGx testing were included before PGx testing. Conclusion In Switzerland, personalized pharmacotherapy has the potential to be improved, as only 0.09% of the studied population underwent PGx testing, despite 77.4% claiming PGx drugs.
- 5 October 2023
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 30 (3) , 375-379
Assessing prescription of antibiotics after vaccination against pneumococcal pneumonia; using prescription sequence symmetry analysis
- 5 October 2023
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 30 (3) , 375-379
Assessing prescription of antibiotics after vaccination against pneumococcal pneumonia; using prescription sequence symmetry analysis
- Open Access
- 23 November 2022
- Published by Taylor & Francis in Pharmacogenomics and Personalized Medicine
- Vol. ume 15, 967-976
Utilization of Drugs with Pharmacogenetic Dosing Recommendations in Switzerland: A Descriptive Study Using the Helsana Database
Purpose: In Switzerland 167 drugs on the market contain information about pharmacogenetics in their drug label (PGx drug). Preemptive pharmacogenetic testing is reimbursed by health care insurance for only seven drugs (abacavir, carbamazepine, 6-mercaptopurine, azathioprine, 5-fluorouracil, capecitabine, and irinotecan) although, it is proposed to be a cost-effective approach to personalized medicine. The aim of this study was to describe the use of PGx drugs and their corresponding genes in Switzerland. Methods: We identified 90 drugs with dosing recommendations from the Pharmacogenetic Knowledgebase involving 24 genes. We assessed the utilization of those drugs between 2016 and 2020, using claims data from a large Swiss insurance company (Helsana). Results: Of 841 491 persons with drug claims during the whole study period, 78.7% were exposed to PGx drugs. Ibuprofen, pantoprazole, and tramadol had the highest number of users. Seven genes (CYP2C19, CYP2C9, CYP2D6, SLCO1B1, HLA-B, MT-RNR1, and VKORC1) were responsible for over 95% of all potential drug-gene interactions. Conclusion: The prevalence of PGx drug prescriptions is high in the Swiss population. Therefore, intensified preemptive testing may be a useful option as a substantial amount of the Swiss population might benefit.
- 23 November 2022
- Published by Taylor & Francis in Pharmacogenomics and Personalized Medicine
- Vol. ume 15, 967-976
Open AccessUtilization of Drugs with Pharmacogenetic Dosing Recommendations in Switzerland: A Descriptive Study Using the Helsana Database
Purpose: In Switzerland 167 drugs on the market contain information about pharmacogenetics in their drug label (PGx drug). Preemptive pharmacogenetic testing is reimbursed by health care insurance for only seven drugs (abacavir, carbamazepine, 6-mercaptopurine, azathioprine, 5-fluorouracil, capecitabine, and irinotecan) although, it is proposed to be a cost-effective approach to personalized medicine. The aim of this study was to describe the use of PGx drugs and their corresponding genes in Switzerland. Methods: We identified 90 drugs with dosing recommendations from the Pharmacogenetic Knowledgebase involving 24 genes. We assessed the utilization of those drugs between 2016 and 2020, using claims data from a large Swiss insurance company (Helsana). Results: Of 841 491 persons with drug claims during the whole study period, 78.7% were exposed to PGx drugs. Ibuprofen, pantoprazole, and tramadol had the highest number of users. Seven genes (CYP2C19, CYP2C9, CYP2D6, SLCO1B1, HLA-B, MT-RNR1, and VKORC1) were responsible for over 95% of all potential drug-gene interactions. Conclusion: The prevalence of PGx drug prescriptions is high in the Swiss population. Therefore, intensified preemptive testing may be a useful option as a substantial amount of the Swiss population might benefit.